Emerging P2Y12 receptor antagonists: Role in coronary artery disease

Current Vascular Pharmacology

Volumn 8, Issue 1, 2010, Pages 93-101

  Oliphant, Carrie S ^a   Doby, J Bradford ^a   Blade, Crystal L ^b   Das, Kanak ^c   Mukherjee, Debabrata ^d   Das, Pranab ^e  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cangrelor; P2Y12 receptor antagonists; Prasugrel; Ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ARC 69931MX; CANGRELOR; CLOPIDOGREL; EFFIENT; EFIENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; ADENOSINE PHOSPHATE; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PRODRUG; PURINERGIC P2 RECEPTOR; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BLEEDING; BRUISING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPISTAXIS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HEART RUPTURE; HEART VENTRICLE FUNCTION; HEMATURIA; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PURPURA; REVIEW; SIDE EFFECT; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ANIMALS; CORONARY ARTERY DISEASE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRODRUGS; RECEPTORS, PURINERGIC P2; THIOPHENES;

EID: 77949495976     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110790226615     Document Type: Review

References (69)

1. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
3. Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug responsiveness. Am Heart J 2008; 155: 591-9.
4. CAPRIE steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
5. The Clopidogrel in unstable angina to prevent recurrent events (CURE) trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
6. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
7. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C, et al. for the CREDO investigators. Early and sustained dual antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
8. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. for the CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
9. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224-32.
10. COMMITT (Clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
11. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15: 117-25.
12. Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 2004; 10: 9-18.
13. Diener H-S, Bogousslavsky J, Brass ML, Cimminiello C, Csiba L, Kaste M, et al. on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
14. Sacco RL, Diener H-C, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. for the PROFESS study group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
15. Airee A, Draper HM, Finks SW. Aspirin resistance: disparities and clinical implications. Pharmacotherapy 2008; 28: 999-1018.
16. Gasparyan A, Watson T, Lip G. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-43.
17. Zimmerman N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-90.
18. Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, et al. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol 2008; 52: 475-84.
19. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157-64.
20. Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
21. DeMiguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
22. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2006; 47: 27-33.
23. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-9.
24. Pregowski J, Witkowski A, Sitkiewicz D. Significance of aspirin and clopidogrel resistance in patients undergoing percutaneous coronary interventions. Curr Vasc Pharmcol 2007; 5: 135-40.
25. Angiolillo D. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103: 27A-34A.
26. Siller-Matula J, Spiel A, Lang I, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-5.
27. Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA study. J Am Coll Cardiol 2008; 51: 256-60.
28. Ho P, Maddox T, Wang L, Fihn S, Jesse R, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
29. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
30. Mega J, Close S, Wiviott S, Shen L, Hockett R, Brandtt JD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
31. Husted S. New developments in oral antiplatelet therapy. Eur Heart J Suppl 2007; 9: D20-7.
32. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008; 156: S3-S9.
33. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 2007; 67: 613-46.
34. Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost 2003; 9: 115-20.
35. Patti G, Colonna G, Pasccri V, Pepe L, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 study. Circulation 2005; 111: 2099-106.
36. von Beckrath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effect of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE trial. Circulation 2005; 112: 2946-50.
37. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes; the ALBION trial. J Am Coll Cardiol 2006; 48: 931-8.
38. Angiolillo D, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008; 156: S10-5.
39. Jakubowski J, Payne C, Brandt J, Weerakkody GJ, Farid NA, Small DA, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006; 47: 377-84.
40. Brandt J, Payne C, Wiviott S, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-16.
41. Riley A, Tafreshi M, Haber S. Prasugrel: A novel antiplatelet agent. Am J Health-Syst Pharm 2008; 65: 1019-28.
42. Jernberg T, Payne C, Winters K, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-73.
43. 12 antagonist, with clopidogrel in percutaneous coronary intervention. Circulation 2005; 111: 3366-73.
44. Wiviott S, Trenk D, Frelinger A, O'Donoghue M, Neuman FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation 2007; 116:2923-2932.
45. Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
46. Antman EM, Wiviott SD, Murphey SA, Voitk J, Hasin Y, Widimsky P, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 analysis. J Am Coll Cardiol 2008; 51; 2028-33.
47. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-9.
48. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Hermman JPR, et al. Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial. Lancet 2008; 371: 1351-63.
49. Effient [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.
50. Efient [package insert]. Madrid, Spain: Lilly SA; 2009.
51. Clinical Trials.gov. Protocol NCT00642174. Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3). www.clinicaltrials.gov/ct/show/ NCT00642174 (accessed 2008 Nov 21).
52. Clinical Trials.gov Protocol NCT00699998. A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS). www.clinicaltrials.gov/ct/show/NCT00699998 (Accessed 2008 Nov 21).
53. 12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 2006; 27: 1010-12.
54. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47.
55. Cannon CP, Husted S, Harrington RA, Dcirica BM, Emanuelsson H, Peters G, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-51.
56. 12 antagonist, compared with clopidogrel in patients with acute coronary syndrome. J Am Coll Cardiol 2007; 50: 1852-6.
57. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, for the PLATO Investigators. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1046-57.
58. Clinical Trials.gov. Protocol NCT00642811. A Study of the Antiplatelet Effects Comparing AZD6140 With Clopidogrel Responder and Non-Responders (RESPOND). www.clinicaltrials.gov/ct2/show/NCT00642811 (accessed 2008 Nov 7).
59. Price MJ. New antiplatelet therapies in development. Am J Health-Syst Pharm 2008; 65(Suppl 5): S11-15.
60. Storey RF, Oldroyd KG, Wilcox RG. Open multicenter study of the P2Y receptor antagonist AR-C666931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-7.
61. Jacobsson F, Swahn E, Wallentin L, Dellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002; 24: 752-65.
62. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006; 151: 689.e1-10.
63. 12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the safety, tolerability and effect on patency in acute myocardial infarction (STEP-AMI) angiographic trial. Am Heart J 2007; 154: 702-9.
64. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-34.
65. 12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thrombo Haemost 2008; 6: 1153-9.
66. Clinical Trials.gov. Protocol NCT00305162. A Clinical Trial to Demonstrate the Efficacy of Cangrelor (CHAMPION-PCI). www.clinicaltrials.gov/ ct2/show/NCT00305162 (accessed 2008 Nov 30).
67. Clinical Trials.gov. Protocol NCT00385138. Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPTION-Platform). www.clinicaltrials.gov/ct2/show/NCT00385138 (accessed 2008 Nov 30).
68. Clinical Trials.gov. Protocol NCT00767507. Maintenance of Platelet Inhibition with Cangrelor after Discontinuation of Thienopyridines in Patients Undergoing Surgery (BRIDGE). http://www. clinicaltrials.gov/ct2/show/NCT00767507 (accessed 2009 Oct. 1).
69. Clinical Trials.gov. Protocol NCT00645918. Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety (GRAVITAS). www.clinicaltrials. gov/ct2/show/NCT00645918 (accessed 2008 Dec 11).